Engineered immune cells get a metabolic boost to fight blood cancers
NCT ID NCT05702853
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase trial is testing a new version of CAR T-cell therapy that has been modified to improve its energy use, potentially making the cells more effective. It is for adults with certain types of B-cell lymphoma or chronic lymphocytic leukemia that have come back or not responded to treatment. The study will enroll 27 participants to find the safest dose and check for side effects.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Metabolically programmed CAR T-cells targeting CD19
- What this could lead to
- If successful, this could offer a more effective treatment option for patients with certain blood cancers that have not responded to standard therapies.
- What could go wrong
- This is an early-phase trial with only 27 participants, so results may not apply to everyone. There are risks of serious side effects like cytokine release syndrome and neurological problems.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for B-CELL NON-HODGKIN LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Hollings Cancer Center at Medical University of South Carolina
RECRUITINGCharleston, South Carolina, 29425, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can immune cells plus a checkpoint drug outsmart lymphoma?
- Can an immune booster outsmart brain lymphoma?
- A shot at safer CAR t: early brain protection for lymphoma patients?
- Can a Low-Dose antifungal shield vulnerable patients from deadly fungal infections?
- Can a Triple-Drug combo wipe out Slow-Growing lymphomas?
- Can a gentler chemo prep make stem cell transplants safer for blood cancer patients?